RE Assist
Solving the Co-Pay Dilemma
Manufacturers think CMS bars them from helping Medicare patients afford their medicines. This is incorrect. There are solutions!
The Problem: Out of pocket cost dramatically impacts prescription abandonment rates
As novel therapies enter the market patient out-of-pocket costs are increasing. These higher out-of-pocket costs are causing patients to abandon scripts.
This problem is even worse for Medicare patients, primarily due to the Medicare Part D standard benefit design – where Part D patients have NO prescription out-of-pocket maximum. Now consider the fact that 50% of Medicare patient average income is less than $26,200 a year – prescription out-of-pocket costs be insurmountable.
Half of all Medicare beneficiaries had incomes below $26,200 per person in 2016
Medicare Part D beneficiaries often pay thousands of dollars out of pocket for specialty tier drugs, with most costs for many drugs above the catastrophic threshold.
The Solution:
RE has developed the RE Assist Tool!
Easy to navigate dashboards detailing information about 501(c)(3) foundations and their current fund status updated every 5 minutes.
Benefits of the RE Assist Tool
- Fund information is easily referenced at a glance in a fraction of the time case managers currently spend on gathering this information
- Made to ensure compliant and consistent information is being shared with all patients
- Subscribe to receive PUSH notifications when funds open or close
- Tool exists outside of the manufacturer PSS program
For more information please email info@realendpoints.com.